United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trial Experience
Lead Author: Steven E. Arnold, MD
Published: American Academy of Neurology (AAN)
Date: April 4, 2022
Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership
Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 13 - 16, 2022
Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (A35- 004 PHOENIX): Study Design Overview
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 8, 2021
Long-Term Functional Benefits and Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 7, 2021
Safety and Biological Activity of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer's Disease: Results from the Phase 2a PEGASUS Study
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: November 9 - 12, 2021
Longer Overall Survival in the CENTAUR Trial: A Rank-Preserving Structural Failure Time Model Adjusts for Crossover From Placebo to Sodium Phenylbutyrate (PB)/Taurursodiol (TURSO)
Lead Author: Sabrina Paganoni, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 7, 2021
Design of a Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 6, 2021
Functional and Survival Benefit of Sodium Phenylbutyrate–Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: International Congress on Neuromuscular Diseases (ICNMD)
Date: May 21 - 22, 2021 & May 28 - 29, 2021
Design of the International, Randomized, Placebo-Controlled Phase 3 PHOENIX Trial of AMX0035 in Amyotrophic Lateral Sclerosis
Lead Author: Leonard H. van den Berg, MD, PhD
Published: European Network to Cure ALS (ENCALS)
Date: May 12 - 14, 2021
Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS
Lead Author: Sabrina Paganoni, MD, PhD
Published: American Academy of Neurology (AAN)
Date: April 19, 2021